TOKYO-Meiji Seika Pharma Co., Ltd. Ltd. (Headquarters: Tokyo, President & Representative Director: Daikichiro Kobayashi), a leading Japanese pharmaceutical company specializing in infectious diseases, vaccines and hematology, today announced that it has established a new office in the Boston area, USA, and is initiating venture investments in the fields of life sciences and healthcare. Through its investment activities, Meiji Seika Pharma aims to discover and develop cutting-edge therapies and contribute to meeting the medical needs of patients around the world, demonstrating the company’s unwavering commitment to innovation and global health.
The original-language text of this announcement is the official and authoritative version. This translation is intended as an aid only and should be cross-referenced with the original-language text, which is the only version of the text intended to have legal validity.
Contacts
For further information, please contact:
Sho Takahata
Boston Office (“START Office”), Meiji Pharma USA Inc.
Email: mpu.start@meiji.com
